Cargando…

A novel combinatorial cancer immunotherapy: poly-IC and blockade of the PD-1/PD-L1 pathway

A non-antigen specific immunotherapy consisting of repeated co-administration of poly-IC and blocking antibodies targeting the programmed cell death-1 (PD-1) pathway dramatically inhibits tumor development in several mouse models of cancer. Tumor-reactive CD8(+) T cells mediate the antitumor effects...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nagato, Toshihiro, Celis, Esteban
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2014
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063146/ https://www.ncbi.nlm.nih.gov/pubmed/25050210 http://dx.doi.org/10.4161/onci.28440

Ejemplares similares

Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more
por: Turnis, Meghan E., et al.
Publicado: (2012)

Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer
por: Peng, Weiyi, et al.
Publicado: (2013)

Blockade of PD-1 immunosuppression boosts CAR T-cell therapy
por: John, Liza B, et al.
Publicado: (2013)

Targeting HSP90 sensitizes pancreas carcinoma to PD-1 blockade
por: Liu, Jiao, et al.
Publicado: (2022)

Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression
por: Deng, Liufu, et al.
Publicado: (2014)

Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes
por: Robert, Lidia, et al.
Publicado: (2014)

Anti-PD-1 antibodies for the treatment of B-cell lymphoma: Importance of PD-1(+) T-cell subsets
por: Chu, Fuliang, et al.
Publicado: (2014)

PD-L1 immune suppression in cancer: Tumor cells or host cells?
por: Kleinovink, Jan Willem, et al.
Publicado: (2017)

Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy
por: Wei, Huafeng, et al.
Publicado: (2014)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
por: Zhang, Min, et al.
Publicado: (2019)

PD-L1 expression and tumor-infiltrating lymphocytes: Revisiting the antitumor immune response potential in breast cancer
por: Schalper, Kurt A
Publicado: (2014)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

When unity makes strength: Combinatorial NK cell-based immunotherapies against melanoma
por: Messaoudene, Meriem, et al.
Publicado: (2014)

Radiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens
por: Gameiro, Sofia R, et al.
Publicado: (2014)

Is Weak Acid Beneficial for Addressing Checkpoint Inhibitor–Triggered Cancer Hyper Progression in Anti-PD1/PD-L1 Immunotherapies?
por: Wan, Yulin, et al.
Publicado: (2020)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
por: Jia, Long, et al.
Publicado: (2018)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
por: Escors, David, et al.
Publicado: (2022)

Author Correction: TAS0314, a novel multi-epitope long peptide vaccine, showed synergistic antitumor immunity with PD-1/PD-L1 blockade in HLA-A*2402 mice
por: Tanaka, Yuki, et al.
Publicado: (2022)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

Out of the bitter came forth sweet: Activating CD28-dependent co-stimulation via PD-1 ligands
por: Ankri, Chen, et al.
Publicado: (2014)

Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies
por: Lipson, Evan J.
Publicado: (2013)

Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade
por: Serganova, Inna, et al.
Publicado: (2016)

Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy
por: Yuan, Yu, et al.
Publicado: (2021)

PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma
por: Hirata-Nozaki, Yui, et al.
Publicado: (2019)

Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition
por: Codarri Deak, Laura, et al.
Publicado: (2023)

DKK1 as a novel target for myeloma immunotherapy
por: Qian, Jianfei, et al.
Publicado: (2012)

Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes
por: Zheng, Dan, et al.
Publicado: (2022)

Blockade of PD-1/PD-L1 Promotes Adoptive T-Cell Immunotherapy in a Tolerogenic Environment
por: Blake, Stephen J. P., et al.
Publicado: (2015)

Immunotherapy of alveolar echinococcosis via PD‐1/PD‐L1 immune checkpoint blockade in mice
por: Wang, Junhua, et al.
Publicado: (2018)

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
por: Ren, Daixi, et al.
Publicado: (2020)

Combination immunotherapy of glioblastoma with dendritic cell cancer vaccines, anti-PD-1 and poly I:C
por: Zhu, Ping, et al.
Publicado: (2023)

The approval of sintilimab for classical Hodgkin's lymphoma: views and perspectives of anti-PD-1/PD-L1 antibodies in China
por: Deng, Mi
Publicado: (2019)

CDK1/2/5 blockade: killing two birds with one stone
por: Liu, Jiao, et al.
Publicado: (2021)

Application of PD-1 Blockade in Cancer Immunotherapy
por: Wu, Xiaomo, et al.
Publicado: (2019)

Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC
por: Lin, Weimin, et al.
Publicado: (2018)

A novel pathway links telomeres to NK-cell activity: Implications for immunotherapy
por: Cherfils-Vicini, Julien, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_vm4bm5k7glm3a5o4ofva380emk